Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

June 7, 2021

Study Completion Date

January 31, 2022

Conditions
Gastric Cancer in SituPancreatic CancersBiliary Cancers
Interventions
DRUG

Oxaliplatin

Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression

DRUG

Albumin-Bound Paclitaxel /nab-Paclitaxel

150 mg/m2 IVD 30 min bi-weekly.

DRUG

S-1

Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.

DRUG

LV

LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression

Trial Locations (1)

Unknown

Taiwan Cooperative Oncology Group, National Health Research Institutes, Taipei

All Listed Sponsors
collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

National Taiwan University Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER

NCT03162510 - Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers | Biotech Hunter | Biotech Hunter